Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire Sheds Dermagraft; Exits Regenerative Medicine

This article was originally published in The Pink Sheet Daily

Executive Summary

The Irish specialty pharma has divested an underperforming unit, but not without a significant write-off. Yet, investors and analysts applaud the decision.

Advertisement

Related Content

Market Intel: Intense Competition, Innovation Drive Healing Trends In Wound Care
Sanofi Should Take Note: As CEO Picks, Insiders Have History On Their Side
Sanofi Should Take Note: As CEO Picks, Insiders Have History On Their Side
Sanofi Should Take Note: Insiders Might Just Make Better CEOs
Shire Course Corrects Lifitegrast And Eyes Ophthalmology Prospects
Spurring Innovation While Economizing On R&D Spending Remains Industry-Wide Challenge
With Shire Behind Him, Jonas Starts New Chapter At SAGE
Newly Appointed Head of Regenerative Medicine At Shire Plans Rapid Growth For The Division
Advanced BioHealing To Bring Regeneration To Shire

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS076396

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel